85 related articles for article (PubMed ID: 15652762)
1. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
2. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
Mitchell MS; Lund TA; Sewell AK; Marincola FM; Paul E; Schroder K; Wilson DB; Kan-Mitchell J
Cancer Immunol Immunother; 2007 Mar; 56(3):287-301. PubMed ID: 16874487
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).
Kohlgraf KG; Gawron AJ; Higashi M; VanLith ML; Shen X; Caffrey TC; Anderson JM; Hollingsworth MA
Cancer Immunol Immunother; 2004 Dec; 53(12):1068-84. PubMed ID: 15696607
[TBL] [Abstract][Full Text] [Related]
4. Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.
Atzin-Méndez JA; López-González JS; Báez R; Arenas-Del Angel MC; Montaño LF; Silva-Adaya D; Lascurain R; Gorocica P
Oncol Rep; 2016 Jan; 35(1):33-42. PubMed ID: 26498650
[TBL] [Abstract][Full Text] [Related]
5. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; van Zanten-Przybysz I; Hummel P; Nijman HW; Kenemans P; Hilgers J
Cancer Immunol Immunother; 1999 Apr; 48(1):47-55. PubMed ID: 10235488
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
Sarkar S; Salyer AC; Wall KA; Sucheck SJ
Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
[TBL] [Abstract][Full Text] [Related]
7. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines.
Acres B; Apostolopoulos V; Balloul JM; Wreschner D; Xing PX; Ali-Hadji D; Bizouarne N; Kieny MP; McKenzie IF
Cancer Immunol Immunother; 2000 Jan; 48(10):588-94. PubMed ID: 10630311
[TBL] [Abstract][Full Text] [Related]
8. Mucin-1-related T cell infiltration in colorectal carcinoma.
Mulder WM; Stukart MJ; de Windt E; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1996 Jul; 42(6):351-6. PubMed ID: 8830738
[TBL] [Abstract][Full Text] [Related]
9. TG4010: a vaccine with a therapeutic role in cancer.
Arriola E; Ottensmeier C
Immunotherapy; 2016 May; 8(5):511-9. PubMed ID: 27140406
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Supekar NT; Lakshminarayanan V; Capicciotti CJ; Sirohiwal A; Madsen CS; Wolfert MA; Cohen PA; Gendler SJ; Boons GJ
Chembiochem; 2018 Jan; 19(2):121-125. PubMed ID: 29120508
[TBL] [Abstract][Full Text] [Related]
12. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
Ramanathan RK; Lee KM; McKolanis J; Hitbold E; Schraut W; Moser AJ; Warnick E; Whiteside T; Osborne J; Kim H; Day R; Troetschel M; Finn OJ
Cancer Immunol Immunother; 2005 Mar; 54(3):254-64. PubMed ID: 15372205
[TBL] [Abstract][Full Text] [Related]
14. A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells.
Andersson E; Henderikx P; Krambovitis E; Hoogenboom HR; Borrebaeck CA
Cancer Immunol Immunother; 1999 Jan; 47(5):249-56. PubMed ID: 10022468
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope.
Park JS; Kim HS; Park MY; Kim CH; Chung YJ; Hong YK; Kim TG
Cancer Immunol Immunother; 2010 May; 59(5):747-57. PubMed ID: 19936747
[TBL] [Abstract][Full Text] [Related]
16. Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry-based de novo sequencing.
Peng W; Giesbers KC; Šiborová M; Beugelink JW; Pronker MF; Schulte D; Hilkens J; Janssen BJ; Strijbis K; Snijder J
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38508723
[TBL] [Abstract][Full Text] [Related]
17. Synthetic self-adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy.
Zhou Y; Li X; Guo Y; Wu Y; Yin L; Tu L; Hong S; Cai H; Ding F
MedComm (2020); 2024 Feb; 5(2):e484. PubMed ID: 38344400
[TBL] [Abstract][Full Text] [Related]
18. Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients.
Domschke C; Schuetz F; Sommerfeldt N; Rom J; Scharf A; Sohn C; Schneeweiss A; Beckhove P
Cancer Immunol Immunother; 2010 Mar; 59(3):479-86. PubMed ID: 19957084
[TBL] [Abstract][Full Text] [Related]
19. CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors.
Dittmann J; Keller-Matschke K; Weinschenk T; Kratt T; Heck T; Becker HD; Stevanović S; Rammensee HG; Gouttefangeas C
Cancer Immunol Immunother; 2005 Aug; 54(8):750-8. PubMed ID: 15614528
[TBL] [Abstract][Full Text] [Related]
20. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen.
Pifferi C; Aguinagalde L; Ruiz-de-Angulo A; Sacristán N; Baschirotto PT; Poveda A; Jiménez-Barbero J; Anguita J; Fernández-Tejada A
Chem Sci; 2023 Mar; 14(13):3501-3513. PubMed ID: 37006677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
